Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone ....

To To Date: August 12, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Outcome of Board Meeting Ref : Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, As intimated vide our letter dated August 05, 2026, Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone and Consolidated) of the Company quarter ended on 30th June, 2026. copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed. 2. Approved the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non- Executive Director to Whole-Time Director, designated as Executive Director, with effect from October 1, 2026, subject to the approval of the Members of the Company at the ensuing Annual General Meeting. 3. Approved the change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole- Time Director to Non-Executive Director, with effect from October 1, 2026, subject to the approval of the Members of the Company at the ensuing Annual General Meeting. 4. Approved the proposal to make investment in the proposed Joint Venture entity to be incorporated in the Republic of the Philippines ("JV Entity") upto INR 09 Crores within investment limit of approval powers of the Board as prescribed under Secton 186 of the Companies act 2013 and subject to compliance with the applicable provisions of the Companies Act, 2013, the Foreign Exchange Management Act, 1999, the Overseas Investment framework, and other applicable laws and regulations. 5. The Board of Directors considered and approved the allotment of 10,00,000 (Ten Lakhs) Warrants to Mr. Shailesh Siroya, Promoter of the Company, on preferential basis, at an issue price of ₹84/- (Rupees Eighty-Four only) per Warrant, aggregating to ₹8,40,00,000/- (Rupees Eight Crores Forty Lakhs only), pursuant to the approval of the Members of the Company obtained through Postal Ballot on 08th August, 2026, and subject to applicable statutory and regulatory approvals, as may be required. The Company has received 25% of the issue price amounting to ₹2,10,00,000/- (Rupees Two Crores Ten Lakhs only) towards the Warrants. Each Warrant shall be convertible into one (1) fully paid-up Equity Share of the Company having face value of ₹10/- each, upon payment of the balance 75% of the issue price, within a period of 18 months from the date of allotment of the Warrants, in accordance with the terms of issue and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws. The details of the allotment, including the ISIN of the underlying Equity Shares, shall be submitted to the Stock Exchanges and Depositories, as applicable. Further details required under Regulation 30 of the SEBI LODR Regulations read with the SEBI Master Circular for items mentioned at Sl. Nos. 2 , 3 (Annexure A) and 4 (Annexure B) are enclosed. The meeting commenced at 04.45 PM and concluded at 05.15 PM on Wednesday, August 12, 2026. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 are given as under. Annexure: A Change of Designations of Directors: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Particulars Mr. Ravindra Kumar Kothari Mr. Virupakshaya Himesh Reason for change Change in designation from Change in designation from Non-Executive Director to Executive Director to Non- Executive Director Subject to Executive Director Subject to Members approval at ensuring Members approval at ensuring AGM AGM Date of appointment/re- Change of Designation will Change of Designation will designation effective from 01st October effective from 01st October 2026 2026 Term of appointment Not applicable (Director Not applicable (Director already on the Board) already on the Board) Brief profile Not applicable (Director Not applicable (Director already on the Board) already on the Board) disclosure of relationships Not applicable Not applicable between directors (in case of appointment of a director). Information as required under The Director being appointed The Director being appointed Circular No. is not debarred from holding is not debarred from holding LIST/COMP/14/2018- 19 and the office of director by virtue the office of director by virtue NSE/CML/ 2018/02 dated of any SEBI order or any other of any SEBI order or any other June 20, 2018, issued by the such authority. such authority. BSE and NSE, respectively Annexure: B Acquisition: Acquisition of to be incorporated Companies - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SL No Particulars Details 01 Name of the target entity, details in Proposed New Joint Venture Entity to be brief such as size, turnover etc. incorporated in the Republic of the Philippines. Parties Bal Pharma Limited : ("Manufacturer"), a company incorporated under the laws of India, with its principal place of business at Bangalore, India. Hemera International Private Limited : ("Supply Chain Partner"), a company incorporated under the laws of Singapore, with its principal place of business at , Singapore. (Also referred to as Hemera Holdings Pte Limited , Holding Company / Hemera). Turnover: Nil , Size : NA (yet to be commence business operations upon incorporation) 02 whether the acquisition would fall Transactions will not fall within related party within related party transaction(s) and transactions whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length 03 industry to which the entity being Registration, importation, commercialization, acquired belongs; distribution and sale of designated pharmaceutical products Entity Category : Pharmaceutical 04 objects and impact of acquisition To establish a structured collaboration for the (including but not limited to, registration, importation, commercialization, disclosure of reasons for acquisition of market penetration, distribution, and sale of target entity, if its business is outside designated pharmaceutical products in the the main line of business of the listed Republic of the Philippines , with a strategic entity);` option for subsequent expansion into other ASEAN markets 05 brief details of any governmental or Investment will be subject to applicable laws, regulatory approvals required for the FEMA/ODI regulations and requisite acquisition regulatory approvals of Government of India and Republic of the Philippines. 06 indicative time period for completion Depends on requisite regulatory approvals of the acquisition; 07 consideration - whether cash Bank transfer consideration or share swap or any other form and details of the same 08 cost of acquisition and/or the price at Not Applicable, since it's a newly which the shares are acquired incorporating JV 09 percentage of shareholding / control Not Applicable, since it's a newly acquired and / or number of shares incorporating JV acquired 10 brief background about the entity Not Applicable, since it's a newly acquired in terms of products/line of incorporating JV business acquired, date [Showing first 8,000 characters — download PDF for full document]